.svg)
ADMA: The body's internal brake on nitric oxide
Asymmetric dimethylarginine (ADMA) is a small molecule made when the body modifies certain proteins during normal cell activity. Enzymes add methyl groups to arginine side chains in proteins (protein arginine methyltransferases, PRMTs). When those proteins are broken down, free ADMA is released into the bloodstream. The body clears ADMA mainly by enzymatic breakdown (dimethylarginine dimethylaminohydrolase, DDAH) and by the kidneys. An ADMA blood test measures how much of this naturally occurring byproduct is circulating.
ADMA matters because it is an internal "brake" on nitric oxide production. It competes with L-arginine at nitric oxide synthase (especially endothelial NOS, eNOS), lowering nitric oxide (NO) availability. NO is the signal that helps blood vessels relax, supports smooth blood flow, and keeps the vessel lining (endothelium) functioning well. By gauging ADMA, the test reflects the state of the NO pathway and endothelial biology—processes tied to vascular tone, microcirculation, and cardiometabolic and kidney physiology.
Why endothelial health hinges on the NO pathway
ADMA (asymmetric dimethylarginine) is the body's own brake on nitric oxide production—the signal that keeps blood vessels relaxed, blood flowing smoothly, platelets calm, and organs well perfused. When ADMA rises, nitric oxide falls, and the whole vascular network—from heart and brain to kidneys and placenta—works under more strain. Typical adult results land around 0.3–0.7, and cardiovascularly "within reference ranges" tends to sit toward the lower end.
How to read an ADMA result
When values are on the lower side, they usually reflect strong endothelial health: arteries that dilate easily, steady blood pressure, and efficient oxygen delivery during activity. Many healthy young adults and endurance‑trained people show lower ADMA. In normal pregnancy, lower levels support the increased blood flow the uterus and placenta require. Symptoms are uncommon; some people simply experience naturally lower blood pressure and good exercise tolerance.
Low values usually reflect higher nitric oxide availability from less enzyme inhibition and efficient enzymatic and renal clearance. System effects tend to be easier blood flow and lower vascular resistance; lower values are common in younger adults and during healthy mid‑pregnancy.
When values trend high, they signal reduced nitric oxide bioavailability and endothelial dysfunction. This can show up as higher blood pressure, reduced exercise capacity, or, in men, erectile difficulties. It often accompanies chronic kidney disease (both cause and consequence), insulin resistance and type 2 diabetes, and atherosclerosis. During pregnancy, elevated ADMA is linked with impaired placental blood flow and preeclampsia risk. Children and teens with obesity can exhibit higher ADMA alongside early arterial stiffness.
High values usually reflect reduced nitric oxide generation and endothelial dysfunction, with increased vascular tone. Common correlates include higher blood pressure tendency, reduced exercise tolerance, cold extremities, erectile or sexual arousal difficulties, and slower tissue repair. Levels rise with aging and are elevated in chronic kidney disease (reduced clearance), insulin resistance or diabetes, dyslipidemia, smoking exposure, and systemic inflammation.
What shifts an ADMA value
Interpretation is influenced by renal function, age, and sex hormones; levels often increase after menopause. Assays differ; chromatographic methods are more specific than immunoassays. Some clinicians also examine the L‑arginine:ADMA ratio as a companion index of nitric oxide bioavailability.
Markers that map the vascular story around ADMA
ADMA sits at the crossroads of the L‑arginine–nitric oxide pathway, kidney clearance, and vascular inflammation. Interpreting it alongside SDMA or creatinine (renal function), lipids, A1c, and hs‑CRP helps map endothelial health and long‑term risks for hypertension, heart attack, stroke, kidney disease, and adverse pregnancy outcomes.
What an ADMA number adds to cardiovascular risk tracking
ADMA reflects endothelial health and microcirculation across major organs. For long‑term risk, values toward the lower half of normal are generally linked with better endothelial function. Being in range suggests balanced nitric oxide signaling and vascular homeostasis, supporting steady blood pressure and organ perfusion.
FAQs
ADMA (asymmetric dimethylarginine) is a naturally occurring molecule produced during normal protein turnover. It acts as an internal “brake” on nitric oxide (NO) production by competing with L-arginine at the nitric oxide synthase (NOS) enzyme. By inhibiting NOS, ADMA reduces NO availability, which is crucial for relaxing blood vessels, supporting healthy blood flow, and maintaining endothelial function. Elevated ADMA levels can lead to stiffer arteries, reduced microcirculation, and increased cardiovascular risk.
ADMA is a key marker of endothelial health and nitric oxide signaling. High ADMA levels are associated with reduced NO production, leading to impaired blood vessel relaxation, increased arterial stiffness, and higher blood pressure. This imbalance can contribute to long-term cardiovascular risks such as heart attack, stroke, and heart failure. Monitoring ADMA helps identify early endothelial stress and guides interventions to improve vascular health.
Elevated ADMA levels can result from reduced degradation or clearance (especially in chronic kidney disease), increased production, or inhibition of the DDAH enzyme by oxidative stress, inflammation, or high homocysteine. Risk factors include aging, hypertension, diabetes, metabolic syndrome, dyslipidemia, chronic kidney or liver disease, and smoking. Men may have slightly higher levels than women, and ADMA tends to rise with age.
ADMA is measured using laboratory assays, with mass spectrometry being the most specific method. Interpretation depends on the assay and lab reference ranges. It is most appropriate evaluated alongside L-arginine or the L-arginine/ADMA ratio and kidney function tests. Low ADMA values generally indicate healthy endothelial function, while high values suggest impaired nitric oxide signaling and increased cardiovascular risk.
High ADMA levels can lead to reduced nitric oxide production, resulting in stiffer arteries, poor microcirculation, and decreased kidney filtration. Symptoms may include high blood pressure, exertional fatigue, cold extremities, chest pressure (especially in coronary disease), and erectile dysfunction in men. Chronically elevated ADMA is linked to higher risks of heart attack, stroke, heart failure, and adverse pregnancy outcomes like preeclampsia.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Willeit, P., Freitag, D. F., Laukkanen, J. A., Chowdhury, S., Gobin, R., Mayr, M., Di Angelantonio, E., & Chowdhury, R. (2015). Asymmetric dimethylarginine and cardiovascular risk: Systematic review and meta-analysis of 22 prospective studies. Journal of the American Heart Association, 4(6), e001833. https://doi.org/10.1161/JAHA.115.001833
- Németh, B., Ajtay, Z., Hejjel, L., Ferenci, T., Ábrám, Z., Murányi, E., & Kiss, I. (2017). The issue of plasma asymmetric dimethylarginine reference range: A systematic review and meta-analysis. PLoS ONE, 12(5), e0177493. https://doi.org/10.1371/journal.pone.0177493
- Ridker, P. M. (2016). A test in context: High-sensitivity C-reactive protein. Journal of the American College of Cardiology, 67(6), 712-723. https://doi.org/10.1016/j.jacc.2015.11.037
- De Gennaro Colonna, V., Bianchi, M., Pascale, V., Ferrario, P., Morelli, F., Pascale, W., Tomasoni, L., & Turiel, M. (2009). Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Medical Science Monitor, 15(4), RA91-RA101. https://pubmed.ncbi.nlm.nih.gov/19333216/
- El Brihi, J., & Pathak, S. (2024). Normal and abnormal complete blood count with differential. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK604207/
.avif)
.svg)
.svg)
